Alterola Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABTI research report →
Price Chart
About the company
Alterola Biotech, Inc. is a pharmaceutical company dedicated to the research and development of cannabinoid and cannabinoid-like molecules. The firm primarily focuses on pioneering regulated pharmaceutical products for human and animal health, as well as regulated food items.
- CEO
- David John Hitchcock
- IPO
- 2010
- Employees
- 1
- HQ
- Birkenhead, MR, GB
Get TickerSpark's AI analysis on ABTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $291.90K
- P/E
- -0.11
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -1.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -14.67%
- ROIC
- -14.98%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,896,981
- Net Income
- $-1,542,457+76.2%
- EPS
- $-0.00+77.4%
- OCF Growth
- -2444.8%
- FCF Growth
- -2760.1%
- 52W High
- $0.20
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.52
- RSI (14)
- 0
- Avg Volume
- 206
No earnings-call transcripts are available for ABTI yet.
- Free Float
- 9.6%
- Shares Outstanding
- 1.46B
- Float Shares
- 139.94M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 3, 22 | Bright Green Corp | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABTI coverage
Recent articles, reports, and earnings notes.
No research on ABTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABTI report →